Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00

Posted by Linda Flegge on Apr 24th, 2024

Shares of Pharming Group (NASDAQ:PHAR – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $10.00, but opened at $9.67. Pharming Group shares last traded at $9.67, with a volume of 168 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Thursday, March 14th.

Check Out Our Latest Report on Pharming Group

Pharming Group Trading Down 2.5 %

The stock’s 50-day simple moving average is $10.92 and its 200 day simple moving average is $11.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.06 and a quick ratio of 3.33.

Pharming Group (NASDAQ:PHAR – Get Free Report) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. The business had revenue of $81.20 million for the quarter, compared to the consensus estimate of $71.83 million. Research analysts predict that Pharming Group will post -0.02 earnings per share for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC acquired a new stake in Pharming Group (NASDAQ:PHAR – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 11,715 shares of the company’s stock, valued at approximately $134,000. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.